Sam Tetlow

Sam has a strong track record as a catalyst for life science company growth over the last 15 years and delivering returns in both management and investor roles. In addition to the Chairman role at BioFluidica, Sam is CEO of Grant Engine, a company located in Chapel Hill, N.C. that supports leading life science companies secure non-dilutive funding with win rates that are two to three times the national average. Sam has successful experience as an entrepreneur and investor in life sciences companies such as EpiCypher, where as CEO the Company was named best University Startup of 2016 by U.S. Congress, ILS Genomics (purchased by LabCorp), Immunologix (purchased by Intrexon), Gentris Corporation (Purchased by Cancer Genetics, Inc), and Tranzyme Pharma (IPO in April 2011), among others. Prior to that, Sam was a full time Partner with Research Triangle Ventures, where he led the full cycle of life science investing. Sam has a Bachelor of Science degree from Worcester Polytechnic Institute, honors, and a MBA from UNC Kenan-Flagler Business School.